Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo Nordisk for support.

The ADA’s obesity division went live last June, with a mission of advocating for more equitable access to obesity treatments and greater awareness and education around the condition, all of which the association is hoping will help break down stigmas linked to obesity and enable people to get the care and support they need.

Now, Novo Nordisk is joining the cause. The Danish drugmaker, which sells GLP-1 blockbuster Wegovy and its predecessor Saxenda for obesity, will provide an undisclosed amount of funding in a “multi-year commitment,” per an ADA announcement this week.

In addition to monetary support, the ADA said it’s also working with Novo to “explore further opportunities” to boost awareness and education and find “innovative solutions” to improve obesity care uptake.

The ADA cited estimates that of the approximately 125 million people living with obesity in the U.S., only 10% seek medical help. It pointed to societal stigma and biases, as well as barriers to accessing care, as key factors in that gap.

“At Novo Nordisk, we believe our responsibility to health goes well beyond the medicines we develop. As an inaugural supporter of the Obesity Association, and with more than 25 years dedicated to advancing obesity research and care, we are proud to support a holistic approach to the management of obesity that aids health care professionals and empowers individuals with valuable education, tools, and resources,” Anna Windle, Ph.D., Novo’s senior VP of clinical development, medical and regulatory affairs, said in the release.

“By addressing the complexities of obesity and its related complications, we strive to drive meaningful change that improves health outcomes for people living with obesity,” Windle added.

Novo has a stated “mission to defeat obesity,” including by digging into its underlying biological causes, battling stigma and developing holistic, preventive treatments that go beyond just weight-loss aids.

Its recent efforts in that arena include sharing educational resources on social media and beyond about the genetics of obesity, as well as supporting an Obesity Action Coalition PSA last fall that encouraged viewers with obesity to talk to their doctors about their health.

As for improving access to obesity treatments, Novo has, in recent months, brought down the out-of-pocket price for Wegovy. In March, it began offering a one-month supply to self-paying customers for $499, down from $650—already a discount on the list price of about $1,350 per month. And, just until June 30, new self-pay Wegovy customers will be charged only $199 for a month’s supply, in the wake of the May 22 deadline for compounders to stop selling their knockoff versions of the drug.